Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Cash from Operations (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Cash from Operations for 16 consecutive years, with 4641000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Operations rose 168.89% to 4641000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 3842000.0, a 55.11% increase, with the full-year FY2024 number at 3641000.0, down 114.06% from a year prior.
  • Cash from Operations was 4641000.0 for Q3 2025 at Gyre Therapeutics, up from 2059000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 42298000.0 in Q4 2022 to a low of 24356000.0 in Q1 2021.
  • A 5-year average of 2327736.84 and a median of 100000.0 in 2025 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: tumbled 408.48% in 2021, then surged 339.3% in 2022.
  • Gyre Therapeutics' Cash from Operations stood at 17676000.0 in 2021, then soared by 339.3% to 42298000.0 in 2022, then crashed by 92.06% to 3360000.0 in 2023, then plummeted by 182.08% to 2758000.0 in 2024, then skyrocketed by 268.27% to 4641000.0 in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Cash from Operations are 4641000.0 (Q3 2025), 2059000.0 (Q2 2025), and 100000.0 (Q1 2025).